Introduction
============

West Nile Virus (WNV) is a member of the family Flaviviridae from the genus Flavivirus which also contain other viruses pathogenic to humans such as Zika, dengue, yellow fever, Usutu, and Japanese encephalitis ([@B60]; [@B109]). WNV is maintained in nature in a bird-mosquito cycle with birds acting as amplifying hosts ([@B85]). WNV infects mostly mosquitoes from the *Culex* genus which can potentially transmit the virus to every vertebrate on which they feed ([@B97]; [@B2]; [@B41]; [@B130]; [@B78]). While many bird species do not develop any disease, several species such as crows and jays may die of WNV infection ([@B50]). Mammals, primarily horses and humans are unable to contribute to the transmission cycle and thus are considered dead end hosts ([@B33]).

West Nile Virus infection in humans is mostly asymptomatic, however, in approximately 20% of the cases WNV infection induces a mild disease with influenza like symptoms termed West Nile Fever (WNF), while in less than 1% of cases, mainly in elderly and immunocompromised people, infection results in a severe neuroinvasive disease (WNND) which may lead to death ([@B60]). Horses are more prone to WNV than humans and 10% of infected horses may show neurological signs ([@B29]). Currently, no vaccine or other treatments are available for humans, although inactivated and recombinant vaccines are on the market for horses ([@B127]).

During the last 20 years WNV has spread geographically and is now common in countries in Africa, Europe, the Middle East, North America, and East Asia where it can cause disease outbreaks ([@B109]). While the origin of all WNV lineages and genotypes is most probably Africa ([@B87]), WNV is primarily distributed to other areas by bird migration paths ([@B83]). Such is the case for the introduction of WNV into Europe which is hypothesized to be mediated by birds migrating from Africa to Europe in the spring ([@B25]). According to two models, long distance WNV dispersal is dependent on birds while short distance diffusion of the virus is mediated by mosquitoes ([@B75]; [@B84]). Other factors contributing to WNV spread and its ability to cause human infection include short- and long-distance migratory species ([@B118]), wind patterns ([@B83]) and the existence of compatible mosquito vector. Studies in Israel, a major crossroad for bird migration between Africa and Eurasia, have indicated that four different genotypes within two lineages of WNV have been circulating in recent years ([@B78]). Due to its complex transmission cycle and lack of treatment, it is now apparent that a multi-disciplinary approach with cross sectorial collaboration between organizations from public, animal and environmental health is needed to obtain knowledge on WNV circulation and prevention of WNV transmission. Unfortunately, WNV is not alone in its global expansion: other flaviviruses such as dengue and Zika have spread or emerged in many countries making the diagnosis of flaviviral diseases substantially more challenging. In this review we will focus on the recent studies implementing WNV surveillance of mosquitoes and birds within the One Health initiative which aim to reduce WNV transmission and discuss the molecular and serological methods available for sensitive and specific WNV diagnosis.

Wnv Surveillance Within the One Health Initiative
=================================================

The One Health concept recognizes that the health of humans, animals, and environment are all connected and that only a collaborative inter-disciplinary approach can effectively achieve optimal health outcomes ([@B74]). WNV is transmitted to humans and animals primarily via the amplification of the mosquitoes -- birds' enzootic cycle which is independently controlled by climatic and environmental factors such as temperatures, seasons and water level fluctuations ([@B106]). Therefore, active surveillance of WNV in mosquitoes and birds population in combination with analysis of climatic and environmental data offers an opportunity to detect virus prior to the emergence of disease in equine species or human populations and predict timing and locations of future WNV disease outbreaks. Most important, early detection of WNV may facilitate targeted use of insecticides in the infected area to reduce WNV burden in human and animal populations. The necessity of such surveillance schemes is dependent on WNV prevalence and might be implemented in the whole country or restricted to specific region of high WNV endemicity. In the next sections we discuss eight WNV endemic countries which represent several levels of implementation of the One Health concept (**Table [1](#T1){ref-type="table"}**).

###### 

West Nile Virus (WNV) incidence in humans and surveillance programs in selected countries.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country             Disease incidence in humans                                                                                                                                                                                                                                               Status of surveillance programs                                                                                                                                        More information (webpage)
  ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------
  **Italy**           Endemic primarily in northern Italy. 173 WNND cases detected in 2008--2015. National incidence and median age for WNND of 1.2/1,000,000 (from 2012 to 2015) and 73 years (2008--2015), respectively ([@B121]).                                                            Integrated surveillance of human, mosquitoes, wild birds, and horses in endemic regions in Italy. Blood donations testing are activated based on surveillance data.    <https://ecdc.europa.eu/en/west-nile-fever>\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                       <http://www.epicentro.iss.it/problemi/westNile/aggiornamenti.asp>

  **Greece**          Outbreaks of WNV infection in 2010--2012 with overall 525 cases. In the 2012 outbreak national incidence of WNND cases varied from 1.7/100,000 in the 30--39 year-olds to 4.22/100,000 in ≥80 years old. Median age was 70 ([@B108]).                                     An integrated entomological surveillance is in place. Animal and human WNV cases are notified and data is shared.                                                      <https://ecdc.europa.eu/en/west-nile-fever>\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                       [http://www.keelpno.gr/en-us/home.](http://www.keelpno.gr/en-us/home.aspx) [aspx](http://www.keelpno.gr/en-us/home.aspx)

  **Spain**           Two human cases in 2010 and 3 in 2016 in Andalusia.                                                                                                                                                                                                                       Sporadic surveillance in mosquitoes. Notifiable disease in humans and horses.                                                                                          <https://ecdc.europa.eu/en/west-nile-fever>

  **Austria**         Seventeen human cases detected in 2010--2017.                                                                                                                                                                                                                             A national WNV task force integrates data on WNV in animals, mosquitoes and humans.                                                                                    <https://ecdc.europa.eu/en/west-nile-fever>\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                       <https://www.ages.at/en/service/services-press/press-releases/westnile-virus-situation-in-austria/>

  **Israel**          Endemic with annual WNV cases ranging between 12 and 429 with a total of 1382 in 2000--2012 ([@B5]). In the last outbreak in 2015 national incidence of WNF and WNND was 1.8/100,000. Median age was 64.7 in live cases and 75.6 in fatal cases ([@B125]).                Mosquito and human data are shared routinely. A strategic inter-ministerial program to integrate data from animals, humans, and mosquitoes was recently initiated.     <https://www.health.gov.il/English/Topics/Diseases/WNF/Pages/StatusReport2018.aspx>

  **Turkey**          Outbreaks of WNV infection in 2010 and 2011 with 47 and 5 cases, respectively.                                                                                                                                                                                            Sporadic studies on WNV seroprevalence in horses and WNV RNA in mosquitoes.                                                                                            

  **United States**   WNV is present in all 48 continental states. Between 1999 and 2016 21,574 WNND cases were detected. In 2017, 1339 WNND cases were detected. In 1999--2016, national incidence of WNND varied from 0.25/100,000 in the 30--39 year-olds to 1.1/100,000 in ≥70 years old.   National surveillance data capture platform -- ArboNET integrates data of WNV in humans, animals and mosquitoes in addition to state specific surveillance programs.   <https://www.cdc.gov/westnile/index.html>

  **Canada**          In 2016 WNV was present in seven provinces with a total of 60 WNND cases. Overall from 2002 to 2016 5614 WNV infection cases were detected.                                                                                                                               Canada conducts ongoing surveillance at the national level in humans, animals, and mosquitoes.                                                                         <https://www.canada.ca/en/public-health/services/diseases/west-nile-virus/surveillance-west-nile-virus.html>

                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Italy
-----

Following the first outbreak of WNV in horses in Italy in 1998 ([@B27]; [@B7]) the Italian government has started in 2001 a national surveillance plan that targeted birds, domestic poultry, horses, mosquitoes, and humans ([@B4]). In recent years this plan, which is carried out in three regions in the Po valley area in northern Italy where WNV is endemic, has developed and is now based on the trans disciplinary and trans-sectorial collaboration between regional institutions involved in public, human, animal, and environmental health ([@B4]; [@B90]; [@B94]; [@B123]; [@B26]). The integrated surveillance system also allows to modulate blood donations screening in the Emilia-Romagna region as only WNV detection by the surveillance system triggers public health interventions on blood donors ([@B103]). To improve the surveillance sensitivity, data sharing mechanisms have been established among the three regions which are aimed at early detection of the viral circulation and reduction of the risk of infection ([@B104]). Since WNV can be transferable through blood donations, seroprevalence of WNV antibodies among blood donors is also examined ([@B110]; [@B111], [@B112]; [@B49]).

Greece
------

West Nile Virus has emerged in Greece in 2010 and caused outbreaks for three consecutive years in both humans and horses ([@B102]; [@B36],[@B37]; [@B99]; [@B20]). Following the 2010 outbreak a strategic framework for an integrated entomological surveillance program was established with the aims to address the impact of current vector control strategies and climate on mosquito population, to analyze the mosquito species composition in WNV affected areas as well as other areas of Greece and to quantify viral circulation, geographic spread and transmission cycle of WNV in mosquitoes ([@B54]; [@B135]; [@B105]). In recent years seroprevalence studies in both humans ([@B69]; [@B137]), chickens ([@B30]), and equine ([@B20]) were initiated to examine the kinetics of WNV prevalence in animals and humans over time.

Spain
-----

The number of WNV cases detected in horses and humans in Spain is significantly smaller than Italy and Greece and so far only two outbreaks with two and three human patients have been recorded in Andalusia, in 2010 and 2016, respectively ([@B52], [@B51]; [@B77]). Nevertheless, monitoring of mosquitoes infected with WNV and screening of WNV seropositivity in humans, horses, and birds in Spain has enabled the detection of WNV circulation years before the occurrence of cases in humans or horses ([@B47]; [@B76]; [@B63]; [@B1]). Currently, surveillance of WNV in Spain is primarily investigated as research projects run by universities and other private institutions and not by the Spanish or municipal government and as such is focused on specific years and/or regions. Recently, risk mapping of WNV circulation in 2015 in Spain was conducted with the hope to improve WNV risk-based surveillance and develop a model for WNV distribution and infection in Spain ([@B126]).

Israel
------

West Nile Virus has been recognized as endemic in Israel since its establishment in 1948. However, despite sporadic cases and a few small outbreaks ([@B17]; [@B48]; [@B65]), WNV was not considered a public health concern until 2000, when a large scale human outbreak occurred ([@B18]; [@B138]). Since then outbreaks of varying magnitudes have been recorded every few years ([@B5]). Following the 2000 outbreak, a national mosquito surveillance system was established which is responsible for entomological analysis of mosquitoes and characterization of WNV circulation in Israel ([@B97]; [@B78]). Furthermore, WNV infections in humans and seropositivity of the population are monitored routinely and are integrated with mosquito surveillance data by the public health division to assess the burden of WNV circulation in Israel and implement appropriate measures ([@B78], [@B79],[@B81]; [@B16]). Recently, the public health and veterinary services, Israel Nature and Park Authorities and the ministry of environmental protection have initiated a program to integrate WNV data obtained from humans, mosquitos, horses, and birds with the aim to develop a true one health initiative for WNV in Israel. Finally, testing of blood donors was initiated in 2017 to assess the extent of alternative routes of WNV transmission to humans in Israel.

Turkey
------

Much like its neighbor, Greece, WNV outbreaks emerged in 2010 and 2011 with 47 and 5 human cases, respectively ([@B64]). Since then several seroprevalence and mosquito surveillance reports confirmed the presence of WNV in Turkey ([@B44], [@B43], [@B42]). A recent study was initiated to provide a risk-assessment of the circulation of mosquito borne flaviviruses in Turkey ([@B45]), however, an integrated national surveillance plan is not yet in place.

Austria
-------

West Nile Virus was first identified in Austria in birds in 2008 ([@B8]) and human infection has been recorded since 2009 ([@B132]). Since then several WNV clinical cases are diagnosed each year in humans ([@B55]; [@B66]). In 2013, a national WNV task force was established which is responsible to integrate all data collected from mosquito surveillance systems, veterinary surveillance of birds and horses and the Austrian Blood Donation System and public health authorities ([@B55]; [@B66]). Altogether, detailed reports of WNV activity in Austria are routinely published and through the combined effort of multiple independently operating agencies WNV activity in Austria is closely monitored ([@B66]).

United States
-------------

West Nile Virus had not been detected in North America before 1999, when a large WNV outbreak occurred in New York City ([@B95]). Phylogenetic studies identified genetic similarity to strains previously identified in Israel, suggesting a Middle Eastern importation ([@B71]). Since then, the 1999 outbreak strain was rapidly displaced by a novel North American genotype (NA/WN02) ([@B35]) which can now be found in all 48 contiguous states and was responsible for large nationwide epidemics in 2003 and 2012 ([@B6]; [@B122]). WNV can be transmitted under lab setting ([@B134]; [@B136]) and in nature ([@B3]; [@B10]) by several mosquito species circulating in the United States. In addition to state specific mosquito surveillance programs ([@B139]; [@B11]; [@B133]; [@B114]), the Centers for disease control and prevention (CDC) has established in 2000 a comprehensive and robust national surveillance data capture platform termed ArboNET in order to monitor WNV patterns in humans, mosquitoes, birds, and other animals and track the progression of WNV activity across the United States ([@B57]). The use of ArboNET, state specific arboviral surveillance systems and environmental monitoring has allowed prediction of a WNV outbreak in the Great Plains, an area with high levels of WNV circulation ([@B32]; [@B38]). However, despite association of WNV outbreaks in the United States with parameters such as urban and ecological habitats ([@B21]), rural irrigated landscapes ([@B39]), increased temperature ([@B59]), several socioeconomic factors such as housing age and community drainage patterns ([@B124]), per capita income ([@B39]), and neglected swimming pool density ([@B119]; [@B58]), no models have been developed that predict how these factors combine to produce outbreaks. Since the Zika virus outbreak in 2015, ArboNET is routinely used for Zika disease reporting, thus allowing the quick integration and dissemination of data across the United States ([@B128]).

Canada
------

Following WNV introduction to the United States, the virus has spread to Canada and was responsible for major outbreaks in 2002 and 2012 in Ontario and Quebec and in 2003 and 2007 in the Prairie Provinces ([@B144]; [@B67]). In order to cope with the disease, integrated mosquito surveillance is routinely performed at the national level and WNV disease is nationally notifiable and reportable ([@B144]). In addition, surveillance data on humans, horses, and birds is shared between all municipalities and blood donations are routinely checked for WNV RNA presence. Data assembly into weekly national reports and studies evaluating the dynamics of WNV transmission using human case prevalence, mosquito surveillance, and climate data ([@B31]; [@B53]; [@B86]) contribute to raising the awareness of WNV in Canada.

Assessment of One Health Initiatives
------------------------------------

At this point it is hard to assess the effects that One Health initiatives have on controlling WNV disease in each country. In Italy, an unbiased quantitative evaluation protocol has been developed to examine the implementation of the One Health approach in order to "fine tune" the system ([@B104]). However, since One Health is a relatively young approach more time in needed to retrospectively examine its effect on reduction of WNV circulation and infection.

Wnv Rna Diagnosis
=================

With the development of molecular biology methods in the 1980s, laboratory diagnosis of viral infections have developed from traditional viral isolation in cell culture which can take days to weeks ([@B73]) to molecular detection of viral genomes which can be achieved in hours. Acute WNV infection in humans can be diagnosed by WNV RNA detection in samples obtained from symptomatic patients. In addition, since WNV can be transferable through blood ([@B107]; [@B88]), screening of blood and organ donations obtained from persons living in WNV endemic areas is important to identify samples that are infected with WNV ([@B113]).

Diagnosis of WNV Acute Infection
--------------------------------

In recent years, the detection of viral genome in bodily fluids by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) has become the routine diagnosis method for many viral infections due to its industry standard format, high levels of repeatability and reproducibility, high sensitivity and specificity, fast turnaround time and ease of use ([@B19]). Unfortunately, for most diseases caused by flaviviruses, including WNF, molecular diagnosis by qRT-PCR of serum, plasma and cerebrospinal fluid (CSF) samples is of limited value for routine diagnosis due to low level and short lived viremia generated by these viruses ([@B23], [@B22]; [@B12]; [@B80]; **Figure [1](#F1){ref-type="fig"}**). Recently, several studies have demonstrated that WNV is retained in the kidneys and can therefore be detected in urine samples for a longer period of time than plasma, CSF or serum ([@B12],[@B14], [@B13], [@B15]). In addition, since WNV was shown to adhere to red blood cells ([@B120]) it can persist for months in whole blood of blood donors ([@B72]). We have recently found that during acute WNV infection WNV RNA can be detected in whole blood, serum, CSF, plasma, and urine samples in 86.8, 26, 16.6, 20 and 58.3% of WNV infected patients, respectively, demonstrating the superiority and effectiveness of WNV RNA detection in whole blood for diagnosis of acute Infection ([@B80]; **Figure [1](#F1){ref-type="fig"}**). Several commercial and in house molecular diagnostic tests with varying sensitivities are available which are different primarily in their amplification target of the viral genome.

![Theoretical depiction of WNV presence in body fluids and WNV immune response. The phases of WNV detection period in serum, urine, and whole blood as well as the IgM and IgG immune response to WNV infection are presented with respect to the day of illness.](fmicb-09-02421-g001){#F1}

Blood and Organ Screening
-------------------------

Transmission of WNV during blood and organ donations has been recorded in the United States ([@B56]) and Europe ([@B89]; [@B34]; [@B116]; [@B62]). As mentioned previously, 80% of WNV infections in humans are asymptomatic and most persons are not aware they have been infected with WNV, especially in areas endemic for WNV ([@B60]). Therefore, screening of blood donations for WNV is performed annually in many countries with WNV endemic circulation, such as the United States, Canada, several countries in the European Union and Israel to assess and reduce the risk of organ transplant and blood recipients for infection with WNV. A few commercial nucleic acid amplification tests (NATs) are on the market which are approved for blood testing from healthy persons ([@B98]; [@B145]; [@B143]), are fully automated, and allow testing on hundreds of plasma samples a day. Due to the low levels of WNV RNA that may be present in healthy, asymptomatic blood donors, these commercial tests need to detect WNV with very high sensitivity and specificity.

Serological Wnv Diagnosis
=========================

Due to the challenges with WNV viral detection, specific antibody testing is currently the most widely used approach for WNV diagnosis. Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies can usually be detected by day 4 and day 8 after onset of symptoms, respectively ([@B22]) and therefore detection of IgM antibodies alone or IgG seroconversion can point to a WNV acute infection (**Figure [1](#F1){ref-type="fig"}**). Numerous commercial kits for WNV antibody detection are available which are primarily based on detection of specific antibodies against the Envelope (E) protein of WNV using either enzyme linked immunosorbent assays (ELISAs) or immunofluorescence tests (IFAs). The advantages of these qualitative assays are that they are very easy to use in a laboratory setting, the results are mostly reproducible and part of their protocol can be automated. However, since WNV IgM can persist in serum for months and even years after infection ([@B115]; [@B22]; [@B91], [@B92]; [@B101], [@B100]) and significant cross reactivity exists between all flaviviruses it is often difficult to diagnose acute WNV infection based on these commercial kits alone. To validate the initial results neutralization assays can be used. Neutralization determines the ability of the antibodies present in the patient's sample to neutralize the virus and therefore it can evaluate the antibody-virus neutralization efficiency ([@B96]) and is considered the gold standard for diagnosis of WNV infection ([@B24]; [@B68]). There are several types of neutralization protocols with similar performance which differ in their sensitivity \[plaque reduction neutralization (PRNT) 50 or PRNT90\], the method of cytopathic effect (CPE) detection (direct, staining, detection with IFA) and the plates used (for PRNT or micro-neutralization).

The Zika epidemic, which emerged in 2015 in Brazil ([@B46]; [@B129]), poses another layer of complication for diagnosis of flaviviruses, including WNV. Due to the high cross-reactivity of Zika virus with other flavivirus antibodies, E protein based ELISAs and neutralization assays encounter difficulties to distinguish between specific flavivirus infections and as a result diagnosis of WNV or dengue virus ([@B70]; [@B9]) in persons with Zika virus background is more challenging. Our experience (unpublished results) with Zika positive patients show high cross reactivity with WNV E protein based ELISAs which can cause false positive results for encephalitic patients and as a consequence the wrong treatment. The development of ELISA tests for Zika infection which use the Non-structural 1 (NS1) protein as antigen for Zika antibody testing proved to be advantageous and more specific than E protein based ELISAs ([@B131]), however, sensitivity and detection times issues, especially in countries with previous dengue ([@B131]) and possibly WNV ([@B82]) background limit the dependence on this test. Development of similar NS1 antibody based ELISA assays for WNV and dengue virus could be useful in reducing the cross-reactivity resulting in more specific Flavivirus diagnostic tests.

Novel Methods for Wnv Detection
===============================

Serological methods aided by detection of viral nucleic acid by qRT-PCR will, most probably, continue to be the primary and preferred diagnostic methods for WNV. Nevertheless, the establishment of next generation sequencing (NGS) methods in recent years, which are also called deep or high-throughput sequencing, led to the increased use of NGS to complement diagnosis and monitoring of infectious diseases caused by both bacteria ([@B40]) and viruses ([@B61]; [@B28]; [@B117]). The most important diagnostic application for NGS is probably the unbiased identification of pathogens in clinical samples. With regards to WNV, one example is the identification of WNV by NGS from a CSF sample obtained from a 14 years old meningoencephalitis patient ([@B141]). In a recent study, plasma samples from 12 cases of unexplained febrile illness in Tanzania were investigated by NGS and identified WNV in two samples ([@B140]). These examples demonstrate the additive value that NGS may provide even in diagnosis of viruses with short viremia such as WNV. NGS can also be used in epidemiological investigations and research ([@B142]).

Recently, a new and novel method for the detection of flavivirus RNAs including Zika, dengue and WNV from body fluids has emerged. Using CRISPR-cas13 technology, a fluorescent protein was used to track and detect flavivirus RNAs present in patients samples generating a field-deployable viral diagnostic platform with high performance and minimal equipment or sample processing requirements ([@B93]). This platform is comparable in its sensitivity to qRT-PCR assays, is fast (under 2 h) and may be used to serve as a diagnostic platform in areas with limited resources or even compete with current molecular diagnostic devices which are in the market.

Concluding Remarks
==================

The emergence and geographical spread of WNV in recent years has forced endemic countries to initiate integrated surveillance programs to identify, predict, and reduce WNV circulation. Future programs should be implemented to combine all data and assess the effectiveness of these surveillance programs to reduce the burden of WNV infections. In addition, due to the influx of other flaviviruses, such as Zika virus, and their global expansion, more specific, yet sensitive assays for WNV diagnosis should be established to be able to distinguish between the different diseases and ultimately pave the way for the development of a WNV vaccine.
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